PF-06881894 as a single 3- or 6-mg dose prior to definitive surgery, or multiple 6-mg/cycle doses postoperatively, with/without myelosuppressive chemotherapy, was consistent with the clinical pharmacology and safety profile of reference pegfilgrastim.
almost 3 years ago
Clinical • P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal